Linker technology is one of the most important areas of innovation in the antibody drug conjugate market. The linker connects an antibody to its therapeutic payload and influences stability, delivery, and release characteristics.

The global ADC market is forecast to grow from USD 12.62 billion in 2025 to USD 51.1 billion in 2035. This growth reflects rising investment in targeted cancer therapies, improved antibody engineering, and expanding research pipelines. 1097

Modern ADC research focuses on site-specific conjugation, improved payload selection, and linkers designed to remain stable in circulation while releasing the treatment payload in the intended cellular environment. These advances aim to improve the therapeutic index of ADCs.

Pharmaceutical companies are also exploring dual-action drug conjugates and immunomodulatory conjugates. These approaches could broaden the future role of ADC platforms beyond their current use in oncology.

Read more: Antibody Drug Conjugate Market 1097

FAQs

Q1. Why are linkers important in ADCs?
They connect the antibody and payload, influencing drug stability and controlled release.

Q2. What is site-specific conjugation?
It is a method designed to attach the payload at defined locations on an antibody for greater consistency.

Tags: ADC linker technology, site-specific conjugation, oncology innovation, antibody engineering, targeted therapeutics